Ontology highlight
ABSTRACT:
SUBMITTER: Ocana A
PROVIDER: S-EPMC6112749 | biostudies-literature | 2018 Aug
REPOSITORIES: biostudies-literature
Ocaña Alberto A Amir Eitan E Pandiella Atanasio A
Oncotarget 20180807 61
Targeting of HER2-positive tumors with trastuzumab has shown to improve survival in early stage and advanced breast cancer. The addition of pertuzumab, another anti-HER2 antibody, to trastuzumab-containing regimens has demonstrated a modest increase in disease-free survival in the adjuvant setting. Unexpectedly, when pertuzumab was explored in combination with the antibody-drug conjugate TDM1 in the metastatic setting, no additional benefit was observed compared with dual targeting of HER2 with ...[more]